Company visit at Shanghai Bracco Sine Pharmaceutical Corp. Ltd

The Italian Chamber of Commerce in China (CCIC) and its Healthcare Workig Group are pleased to invite you to the upcoming company visit at Shanghai Bracco Sine Pharmaceutical Corp. Ltd., that will be held on September 14th, starting from 14:00 (China time) in Shanghai.

Why participate?

The event aims the participants with an inside view of how the Bracco Group, an Italian company leading in Diagnostic Imaging, operates in the Chinese healthcare market. Through presentations and a guided plant tour, participants will gain insights into Bracco industrial footprint in Pudong, its quality and innovation standards, and its role in the R&D, production, marketing and distribution of Contrast Media and Imaging Solutions for hospitals across China. The event is designed to foster dialogue between Italian and Chinese businesses, share best practices in healthcare and pharmaceuticals, and create opportunities for future collaboration within the life sciences ecosystem.

Agenda

• 14:00–14:30 Registration
• 14:30–14:35 Welcome Open Speech
• 14:35–14:40 CCIC Board Member Greetings
• 14:40–14:50 Introduction of HCWG
• Elena Barboni, BD Director of Flamma S.P.A. and Coordinator of CCIC HCWG
• 14:50–15:10 Introduction of Bracco Sine China
• Valtero Canepa, CEO APAC Bracco Sine
• 15:10-15:30 Q&A
• 15:30–15:50 Coffee break and preparation for plant tour
• 15:50-16:50 Bracco Sine plant guided tour
• 16:50–17:00 Closure & regards

Event details:

• Date: 14th September 2026
• Time: 14:00-17:00 (China time)
• Format: offline
• Venue: Shanghai Bracco Sine Pharmaceutical Corp. Ltd.
• Address: No.121 T3-4, Longgui Road Tangzhen, Pudong New Area, Shanghai 上海市浦东新区唐镇龙桂路121号T3-4
• Language: English
• Transportation: A shuttle bus will be organized from CCIC SH office to Shanghai Bracco from 13:00 pm (Address: 上海市徐汇区长乐路989号世纪商贸广场 The Center, 989 Changle Road, Xuhui District, Shanghai)

CCIC Members 150 RMB

CCIC Non-Members 230 RMB

CCIC Young Professionals Network 100 RMB

Refund policy: refunds are available only within 24 hours before the event.

For more information contact us at: w.chen@cameraitacina.com

Bracco Group, founded in 1927 and headquartered in Milan, Italy, is a global leader in diagnostic imaging, committed to advancing healthcare and improving people's lives by shaping the future of prevention and precision medicine.

The Group operates in the healthcare sector across more than 100 countries, with around 3,800 employees and consolidated annual revenues of approximately €2 billion.

Bracco develops, manufactures and markets a broad portfolio of pharmaceutical products for diagnostic imaging, including contrast agents for X‑ray and Computed Tomography (CT), gadolinium‑based agents for Magnetic Resonance Imaging (MRI), microbubbles for Contrast Enhanced Ultrasound (CEUS), and radiopharmaceuticals and PET tracers for Molecular Imaging, together with specialized medical devices, advanced contrast management technologies and software solutions.

Group's manufacturing network spans Italy, Switzerland, U.S., Japan and China, supported by R&D centers in Italy, Switzerland, U.S., China and a wide range of collaborations with universities and scientific institutions worldwide.

Bracco invests about 10% of its imaging turnover in Research & Development and holds a portfolio of more than 2,500 patents, reflecting a long‑standing commitment to innovation and to addressing unmet clinical needs.

The Group's strong focus on sustainability is demonstrated by its top‑tier EcoVadis rating and by a comprehensive ESG strategy covering environment, ethics, labour and human rights, and sustainable procurement across its global operations.

The Group also operates in healthcare services through Centro Diagnostico Italiano (CDI), an outpatient diagnostic network based in Milan, and promotes culture, science and social inclusion through Fondazione Bracco, underlining its broader commitment to society and corporate social responsibility.

In China Bracco operates three companies: BraccoSine, a pharmaceutical JV with the Shanghai Pharma group, where Bracco owns 70% of the share, Bracco Imaging Medical Technologies, a WFOE specialized in medical devices and R&D and Bracco Far East, a commercial affiliate in Hong Kong.